What is the recommended treatment for cellulitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Cellulitis

Beta-lactam monotherapy is the standard of care for typical uncomplicated cellulitis and should be your first-line treatment, with oral agents such as cephalexin, dicloxacillin, or amoxicillin for 5 days. 1, 2

First-Line Antibiotic Selection for Uncomplicated Cellulitis

For outpatient management of typical nonpurulent cellulitis:

  • Oral beta-lactam monotherapy is successful in 96% of cases because β-hemolytic streptococci and methicillin-sensitive S. aureus are the primary pathogens 1, 3
  • Recommended oral agents include:
    • Cephalexin (preferred by many clinicians) 1
    • Dicloxacillin 250-500 mg every 6 hours 1
    • Amoxicillin 1, 2
    • Amoxicillin-clavulanate (Augmentin) 875/125 mg twice daily 1
    • Clindamycin 300-450 mg every 6 hours (covers both streptococci and MRSA if local resistance <10%) 1, 2

Critical point: MRSA is an uncommon cause of typical cellulitis even in high-prevalence settings, so routine MRSA coverage is unnecessary and represents overtreatment 1, 2, 4

Treatment Duration

  • Treat for 5 days if clinical improvement occurs 1, 2
  • Extend treatment only if symptoms have not improved within this 5-day timeframe 1, 2
  • Traditional 7-14 day courses are no longer necessary for uncomplicated cases 1

When to Add MRSA Coverage

Add MRSA-active antibiotics ONLY when specific risk factors are present: 1, 2

  • Penetrating trauma or injection drug use 1
  • Purulent drainage or exudate 1
  • Evidence of MRSA infection elsewhere or known MRSA colonization 1
  • Systemic inflammatory response syndrome (SIRS) 1
  • Failure to respond to beta-lactam therapy after 48-72 hours 1

If MRSA coverage is needed, choose one of these regimens:

  • Clindamycin monotherapy 300-450 mg every 6 hours (covers both streptococci and MRSA, avoiding need for combination therapy) 1
  • Trimethoprim-sulfamethoxazole (Bactrim) PLUS a beta-lactam (e.g., cephalexin) 1
  • Doxycycline 100 mg twice daily PLUS a beta-lactam 1

Common pitfall: Never use doxycycline or Bactrim as monotherapy for typical cellulitis—their activity against β-hemolytic streptococci is unreliable 1, 4

Inpatient/IV Antibiotic Management

For hospitalized patients requiring IV therapy:

Uncomplicated cellulitis without MRSA risk factors:

  • Cefazolin 1-2 g IV every 8 hours (preferred) 1
  • Oxacillin 2 g IV every 6 hours (alternative) 1

Complicated cellulitis or MRSA coverage needed:

  • Vancomycin 15-20 mg/kg IV every 8-12 hours (first-line, A-I evidence) 1
  • Linezolid 600 mg IV twice daily (equally effective alternative, A-I evidence) 1, 5
  • Daptomycin 4 mg/kg IV once daily (A-I evidence) 1
  • Clindamycin 600 mg IV every 8 hours (if local MRSA resistance <10%) 1

Severe cellulitis with systemic toxicity or suspected necrotizing fasciitis:

  • Vancomycin 15-20 mg/kg IV every 8-12 hours PLUS piperacillin-tazobactam 3.375-4.5 g IV every 6 hours 1
  • Alternative combinations: vancomycin plus a carbapenem, or vancomycin plus ceftriaxone and metronidazole 1
  • For documented group A streptococcal necrotizing fasciitis: penicillin plus clindamycin 1

Treatment duration for severe infections: 7-14 days guided by clinical response 1

Indications for Hospitalization

Admit patients with any of the following: 1, 2

  • Systemic inflammatory response syndrome (SIRS): fever >38°C, tachycardia >90 bpm, tachypnea >24 rpm 1
  • Hypotension or hemodynamic instability 1
  • Altered mental status or confusion 1
  • Severe immunocompromise or neutropenia 1
  • Concern for deeper or necrotizing infection (severe pain out of proportion to exam, skin anesthesia, rapid progression, gas in tissue, bullous changes) 1

Adjunctive Measures

These interventions accelerate recovery and prevent recurrence: 1, 2

  • Elevate the affected extremity to promote gravitational drainage of edema 1, 2
  • Examine and treat interdigital toe spaces for tinea pedis, fissuring, or maceration 1, 2
  • Address predisposing conditions: venous insufficiency, lymphedema, chronic edema, obesity, eczema 1, 2, 6
  • Consider systemic corticosteroids (e.g., prednisone 40 mg daily for 7 days) in non-diabetic adults, though evidence is limited 1, 2

Special Situations

Bite-associated cellulitis (human or animal):

  • Amoxicillin-clavulanate 875/125 mg twice daily as monotherapy (provides polymicrobial coverage) 1
  • Do NOT add Bactrim to this regimen 1

Penicillin allergy:

  • Clindamycin 300-450 mg every 6 hours (covers both streptococci and MRSA) 1
  • Cefuroxime 500 mg twice daily if only mild penicillin allergy 1

Pediatric dosing:

  • Cephalexin or clindamycin at weight-based doses 1
  • Vancomycin 15 mg/kg IV every 6 hours for hospitalized children 1
  • Never use doxycycline in children <8 years due to tooth discoloration 1

Reassessment and Treatment Failure

Mandatory reassessment at 48-72 hours to verify clinical response: 1

  • If spreading despite appropriate antibiotics, consider:
    • MRSA involvement (switch to vancomycin or add MRSA coverage) 1
    • Necrotizing fasciitis (obtain emergent surgical consultation) 1
    • Misdiagnosis (consider pseudocellulitis: venous stasis dermatitis, contact dermatitis, DVT) 4
    • Abscess requiring drainage 1

Do not continue ineffective antibiotics beyond 48 hours—progression indicates either resistant organisms or a different/deeper infection 1

References

Guideline

Management of Cellulitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cellulitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cellulitis: A Review.

JAMA, 2016

Research

Cellulitis.

Infectious disease clinics of North America, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.